Literature DB >> 23517485

Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial.

Philip Green1, Benson A Babu, Sergio Teruya, Stephen Helmke, Martin Prince, Mathew S Maurer.   

Abstract

Anemia, a common comorbidity in older adults with heart failure and a preserved ejection fraction (HFPEF), is associated with worse outcomes. The authors quantified the effect of anemia treatment on left ventricular (LV) structure and function as measured by cardiac magnetic resonance (CMR) imaging. A prospective, randomized single-blind clinical trial (NCT NCT00286182) comparing the safety and efficacy of epoetin alfa vs placebo for 24 weeks in which a subgroup (n=22) had cardiac magnetic resonance imaging (MRI) at baseline and after 3 and 6 months to evaluate changes in cardiac structure and function. Pressure volume (PV) indices were derived from MRI measures of ventricular volume coupled with sphygmomanometer-measured pressure and Doppler estimates of filling pressure. The end-systolic and end-diastolic PV relations and the area between them as a function of end-diastolic pressure, the isovolumic PV area (PVAiso), were calculated. Patients (75±10 years, 64% women) with HFPEF (EF=63%±15%) with an average hemoglobin of 10.3±1.1 gm/dL were treated with epoetin alfa using a dose-adjusted algorithm that increased hemoglobin compared with placebo (P<.0001). As compared with baseline, there were no significant changes in end-diastolic (-7±8 mL vs -3±8 mL, P=.81) or end-systolic (-0.4±2 mL vs -0.7±5 mL, P=.96) volumes at 6-month follow-up between epoetin alfa compared with placebo. LV function as measured based on EF (-1.5%±1.6% vs -2.6%±3.3%, P=.91) and pressure volume indices (PVAiso-EDP at 30 mm Hg, -5071±4308 vs -1662±4140, P=.58) did not differ between epoetin alfa and placebo. Administration of epoetin alfa to older adult patients with HFPEF resulted in a significant increase in hemoglobin, without evident change in LV structure, function, or pressure volume relationships as measured quantitatively using CMR imaging.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517485      PMCID: PMC3816505          DOI: 10.1111/chf.12027

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  52 in total

1.  Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Authors:  Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

2.  Instantaneous pressure-volume relationships and their ratio in the excised, supported canine left ventricle.

Authors:  H Suga; K Sagawa
Journal:  Circ Res       Date:  1974-07       Impact factor: 17.367

3.  Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging.

Authors:  Theano Papavassiliu; Harald P Kühl; Meike Schröder; Tim Süselbeck; Olga Bondarenko; Christoph K Böhm; Aernout Beek; Mark M B Hofman; Albert C van Rossum
Journal:  Radiology       Date:  2005-06-13       Impact factor: 11.105

4.  Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study.

Authors:  R A Nishimura; C P Appleton; M M Redfield; D M Ilstrup; D R Holmes; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

5.  Prevalence and mortality rate of congestive heart failure in the United States.

Authors:  D D Schocken; M I Arrieta; P E Leaverton; E A Ross
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

Review 6.  Clinical factors influencing sensitivity and response to epoetin.

Authors:  Donald Richardson
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

7.  Erythropoietic response and outcomes in kidney disease and type 2 diabetes.

Authors:  Scott D Solomon; Hajime Uno; Eldrin F Lewis; Kai-Uwe Eckardt; Julie Lin; Emmanuel A Burdmann; Dick de Zeeuw; Peter Ivanovich; Andrew S Levey; Patrick Parfrey; Giuseppe Remuzzi; Ajay K Singh; Robert Toto; Fannie Huang; Jerome Rossert; John J V McMurray; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

8.  Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

Authors:  Mathew S Maurer; Sergio Teruya; Bibhas Chakraborty; Stephen Helmke; Donna Mancini
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

9.  Anemia and heart failure: a community study.

Authors:  Shannon M Dunlay; Susan A Weston; Margaret M Redfield; Jill M Killian; Véronique L Roger
Journal:  Am J Med       Date:  2008-08       Impact factor: 4.965

10.  Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians.

Authors:  Donald S Silverberg; Dov Wexler; Miriam Blum; Doron Schwartz; Gad Keren; David Sheps; Adrian Iaina
Journal:  Isr Med Assoc J       Date:  2003-05       Impact factor: 0.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.